Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study

Diabetes, Obesity & Metabolism
Cristian GujaJulio Rosenstock

Abstract

To compare the efficacy and safety of adding the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes who were inadequately controlled despite titrated insulin glargine (IG) ± metformin. This multicentre, double-blind study (ClinicalTrials.gov identifier: NCT02229383) randomized (1:1) patients with persistent hyperglycaemia after an 8-week titration phase (glycated haemoglobin [HbA1c] 7.0%-10.5% [53-91 mmol/mol]) to exenatide QW or placebo. The primary endpoint was HbA1c change from baseline to week 28. Secondary endpoints included body weight, 2-hour postprandial glucose, and mean daily IG dose. Of 464 randomized patients (mean: age, 58 years; HbA1c, 8.5% [69 mmol/mol]; diabetes duration, 11.3 years), 91% completed 28 weeks. Exenatide QW + IG vs placebo + IG significantly reduced HbA1c (least-squares mean difference, -0.73% [-8.0 mmol/mol]; 95% confidence interval, -0.93%, -0.53% [-10.2, -5.8 mmol/mol]; P < .001; final HbA1c, 7.55% [59 mmol/mol] and 8.24% [67 mmol/mol], respectively); body weight (-1.50 kg; -2.17, -0.84; P < .001); and 2-hour postprandial glucose (-1.52 mmol/L [-27.5 mg/dL]; -2.15, -0.90 [-38.7, -16.2]; P < .001). Significantly more exenatide Q...Continue Reading

References

Aug 13, 2014·Diabetes Care·John B BuseUNKNOWN NN9068-3912 (DUAL-II) Trial Investigators
Jan 17, 2015·Diabetic Medicine : a Journal of the British Diabetic Association·C WangI Idris
Dec 17, 2016·Diabetes Care·UNKNOWN American Diabetes Association
Dec 17, 2016·Diabetes Care·UNKNOWN American Diabetes Association
Jan 18, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez

❮ Previous
Next ❯

Citations

May 1, 2018·Diabetes, Obesity & Metabolism·Ronald M GoldenbergJean-François Yale
May 24, 2018·Journal of Diabetes·Ann M CarracherKelly L Close
Aug 30, 2018·Journal of Managed Care & Specialty Pharmacy·Yehuda HandelsmanDoron Schneider
Aug 30, 2018·Journal of Managed Care & Specialty Pharmacy·Michael HeileMichael Shannon
Feb 8, 2019·Expert Opinion on Pharmacotherapy·Sebastian M HeimbürgerFilip K Knop
Sep 11, 2020·Journal of Clinical Pharmacy and Therapeutics·Dhiren Patel
Sep 11, 2020·Journal of Clinical Pharmacy and Therapeutics·Jennifer Trujillo
Apr 20, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Cristian GujaSerge A Jabbour
Aug 7, 2020·JAAPA : Official Journal of the American Academy of Physician Assistants·Ji Hyun Chun, Amy Butts
Aug 3, 2020·JAAPA : Official Journal of the American Academy of Physician Assistants·Ji Hyun Chun, Amy Butts
Feb 18, 2021·Journal of Pharmacy Practice·Mandy ChenRoda Plakogiannis
Apr 14, 2020·Journal of the American Association of Nurse Practitioners·Basem M MishrikyJames R Powell
Mar 17, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Barrie ChubbMichelle Orme
Jun 25, 2021·Expert Opinion on Pharmacotherapy·Mohamad Sirri TaraziAlpana P Shukla

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02229383

Software Mentioned

INITIATE
SAS

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.